BridgeBio receives FDA priority review for muscular dystrophy drug

May 27, 2026 7:30 AM

BridgeBio Pharma Inc. (NASDAQ: BBIO) announced the FDA has accepted its new drug application for BBP-418, an oral treatment for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found